Estimating Prognosis in HIV-1 Infection
Authors: John P. Phair
Journal: Annals of Internal Medicine (1993)

Editorials1 May 1993Estimating Prognosis in HIV-1 InfectionJohn P. Phair, MDJohn P. Phair, MDNorthwestern University Medical School, Chicago, IL 60611.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-9-199305010-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Progression of infection due to the human immunodeficiency virus type 1 (HIV-1) is highly variable. Cohort studies have estimated that the median time, free of serious complications after HIV-1 infection, is 7 to 11 years [1, 2]. These estimates of the incubation period are based on progression to the acquired immuno-deficiency syndrome (AIDS) as defined by the Centers for Disease Control and Prevention in 1987 [3]. With the change in the definition of AIDS [4], the median duration of AIDS-free time will probably decrease [5].Life-threatening complications of immunosuppression develop after a shorter period of clinical latency in some HIV-1-infected ...References1. Munoz A, Wang M-C, Bass S, Taylor JM, Kingsley LA, Chmiel JS, et al. Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am J of Epidemiol. 1989; 130:530-9. Google Scholar2. Anderson R. The role of mathematical models in the study of HIV-1 transmission and the epidemiology of AIDS. AIDS. 1988; 1:241-56. Google Scholar3. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program Center for Infectious Diseases. MMWR. 1987; 36(1s):3s-15s. Google Scholar4. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992; 41(RR-17):1-19. Google Scholar5. Hoover DR, Graham NM, Chen B, Taylor JM, Phair JP, Zhow SY, et al. Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr. 1992; 5:794-802. Google Scholar6. Phair JP, Jacobson L, Detels R, Rinaldo C, Saah A, Schrager L, et al. Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1992; 5:490-6. Google Scholar7. Tersmette M, Lange J, de Goede R, de Wolfe F, Eftink-Schattenkerks J, Schellenkens P, et al. Association between biologic properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet. 1989; 1:983-5. Google Scholar8. Kaslow R, Duquesnoy R, VanRaden M, Kingsley L, Marrari M, Su S, et al. A1, Cw7, B8, DR3, HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort study. Lancet. 1990; 335: 927-30. Google Scholar9. Webster A, Lee CA, Cook DG, Grundy JE, Emery VC, Kernoff P, et al. Cytomegalovirus infection and progression toward AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet. 1989; 2:63-6. Google Scholar10. Graham NH, Zeger SL, Park LP, Phair JP, Detels R, Vermund SH, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Lancet. 1991; 338:265-9. Google Scholar11. MacDonell K, Chmiel JS, Poggensee L, Wu S, Phair JP. Predicting progression to AIDS: combined usefulness of CD4+ lymphocyte counts and p24 antigenemia. Am J Med. 1990; 89:706-12. Google Scholar12. Phair JP, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. The Multicenter AIDS Cohort Study Group. N Engl J Med. 1990; 322:161-5. Google Scholar13. Pertel P, Hirschtick R, Phair JP, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992; 5:1069-74. Google Scholar14. Farzadegan H, Chmiel J, Odaka N, Ward L, Poggensee L, Saah A, et al. Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4+ lymphocyte number and AIDS-free time. J Infect Dis. 1992; 166:1217-22. Google Scholar15. Redfield RR, Wright DC, Tramont EC. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med. 1986; 314: 131-2. Google Scholar16. MacDonell K, Chmiel J, Goldsmith J, Wallemack C-B, Steinberg J, Byers E, et al. Prognostic usefulness of the Walter Reed staging classification for HIV infection. J Acquir Immune Defic Syndr. 1988; 1:367-74. Google Scholar17. Fahey J, Taylor J, Detels R, Hofmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990; 322:166-72. Google Scholar18. Volberding P, Lagakos S, Koch M, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. N Engl J Med. 1990; 322: 942-9. Google Scholar19. Kahn JO, Lagakos S, Richman DD, Cross A, Pettinelli C, Liou SH, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med. 1992; 327:581-7. Google Scholar20. Meng TC, Fischl MA, Boota AM, Spector SA, Bennett D, Bassiakos Y, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I study. Ann Intern Med. 1992; 116:13-20. Google Scholar21. Horsburgh CR. Mycobacterium avium complex infection in acquired immunodeficiency syndrome. N Engl J Med. 1991; 324: 1332-8. Google Scholar22. Choi S, Lagakos S, Schooley R, Volberding P. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection. Ann Intern Med. 1993; 118: 674-80. Google Scholar23. Koot M, Keet I, Vos A, de Goede R, Roos M, Coutinho RA, et al. Prognostic value of HIV-1 biologic phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993; 118:681-688. Google Scholar24. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989; 321:1621-5. Google Scholar25. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis. 1991; 163:862-6. Google Scholar26. Furtado MR, Murphy R, Wolinsky S. Quantification of human immunodeficiency virus type 1 tat mRMA as a marker for assessing the efficacy of antiretroviral therapy. J Infect Dis. 1993; 167:213-6. Google Scholar27. Patterson B, Till M, Otto P, Goolsby C, Furtado MR, McBride L, et al. Detection of HIV-1 DNA and mRNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science. (In press). Google Scholar28. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, et al. Detection of three distinct patterns of T-helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest. 1989; 84:1892-9. Google Scholar Author, Article, and Disclosure InformationAffiliations: Northwestern University Medical School, Chicago, IL 60611.Corresponding Author: John P. Phair, MD, Suite 1106, 680 N. Lake Shore Drive, Chicago IL 60611. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine Sungsub Choi , Stephen W. Lagakos , Robert T. Schooley , and Paul A. Volberding Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS Maarten Koot , Ireneus P. M. Keet , Aster H. V. Vos , Ruud E. Y. de Goede , Marijke Th. L. Roos , Roel A. Coutinho , Frank Miedema , Peter Th. A. Schellekens , and Matthijs Tersmette Metrics Cited ByResponse of CD4 Lymphocytes and Clinical Consequences of Treatment Using ddI or ddC In Patients with Advanced HIV InfectionExpression of IL-10, IL-4 and interferon-gamma in unstimulated and mitogen-stimulated peripheral blood lymphocytes from HIV-seropositive patientsDietary Intake and Counseling, Weight Maintenance, and the Course of HIV InfectionSIDA. Actualités 1993 1 May 1993Volume 118, Issue 9Page: 742-744KeywordsAIDSAntigensCohort studiesHIV-1LymphocytesPneumoniaProphylaxisResearch assessmentResearch laboratoriesSkin tests Issue Published: 1 May 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...